MIND MEDICINE (MINDMED) INC. Financial Statements (2023 and earlier)
Company Profile
| Business Address |
1166 ALBERNI STEET VANCOUVER, BC V6E 3Z3 |
| State of Incorp. | BC |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2833 - Medicinal Chemicals and Botanical Products (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 142,142 | 133,539 | ||
| Cash and cash equivalents | 142,142 | 133,539 | ||
| Other undisclosed current assets | 3,913 | 3,676 | ||
| Total current assets: | 146,055 | 137,215 | ||
| Noncurrent Assets | ||||
| Intangible assets, net (including goodwill) | 23,607 | 26,787 | ||
| Goodwill | 19,918 | 19,918 | ||
| Intangible assets, net (excluding goodwill) | 3,689 | 6,869 | ||
| Other noncurrent assets | 331 | |||
| Total noncurrent assets: | 23,938 | 26,787 | ||
| TOTAL ASSETS: | 169,993 | 164,002 | ||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 7,988 | 10,408 | ||
| Accounts payable | 2,111 | 4,178 | ||
| Accrued liabilities | 5,877 | 6,230 | ||
| Other undisclosed current liabilities | 9,904 | |||
| Total current liabilities: | 17,892 | 10,408 | ||
| Noncurrent Liabilities | ||||
| Liabilities, other than long-term debt | 1,184 | |||
| Other liabilities | 1,184 | |||
| Other undisclosed noncurrent liabilities | 1,930 | |||
| Total noncurrent liabilities: | 1,184 | 1,930 | ||
| Total liabilities: | 19,076 | 12,338 | ||
| Equity | ||||
| Equity, attributable to parent | 150,917 | 151,664 | ||
| Additional paid in capital | 344,758 | 288,290 | ||
| Accumulated other comprehensive income | 627 | 1,046 | ||
| Accumulated deficit | (194,468) | (137,672) | ||
| Total equity: | 150,917 | 151,664 | ||
| TOTAL LIABILITIES AND EQUITY: | 169,993 | 164,002 | ||
Income Statement (P&L) ($ in thousands)
| 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|
| Revenues (Other Income) | 2 | 106 | |
| Gross profit: | 2 | 106 | |
| Operating expenses | (66,331) | (93,854) | |
| Other undisclosed operating loss | (2) | (106) | |
| Operating loss: | (66,331) | (93,854) | |
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | 9,535 | (339) | |
| Loss from continuing operations before income taxes: | (56,796) | (94,193) | |
| Income tax benefit | 1,157 | ||
| Loss from continuing operations: | (56,796) | (93,036) | |
| Loss before gain (loss) on sale of properties: | ✕ | (93,036) | |
| Net loss available to common stockholders, diluted: | (56,796) | (93,036) | |
Comprehensive Income ($ in thousands)
| 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|
| Net loss: | (56,796) | (93,036) | |
| Comprehensive loss: | (56,796) | (93,036) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (419) | 762 | |
| Comprehensive loss, net of tax, attributable to parent: | (57,215) | (92,274) | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.